Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1995 Aug;63(8):2805–2810. doi: 10.1128/iai.63.8.2805-2810.1995

Comparative immunogenicity of conjugates composed of Escherichia coli O111 O-specific polysaccharide, prepared by treatment with acetic acid or hydrazine, bound to tetanus toxoid by two synthetic schemes.

R K Gupta 1, W Egan 1, D A Bryla 1, J B Robbins 1, S C Szu 1
PMCID: PMC173380  PMID: 7542631

Abstract

Escherichia coli O111, of various H types and virulence factors, causes enteritis throughout the world, especially in young children. This O type is found rarely in healthy individuals. Serum antibodies to the O-specific polysaccharide of O111 lipopolysaccharide (LPS) protect mice and dogs against infection with this E. coli serotype. The O111 O-specific polysaccharide is composed of a pentasaccharide repeat unit with two colitoses bound to the C-3 and C-6 of glucose in a trisaccharide backbone; this structure is identical to that of Salmonella adelaide (O35), another enteric pathogen. Nonpyrogenic O111 O-specific polysaccharide was prepared by treatment of its LPS with acetic acid (O-SP) or the organic base hydrazine (DeA-LPS). The O-SP had a reduced concentration of colitose. These products were derivatized with adipic acid dihydrazide (ADH) or thiolated with N-succinimidyl-3(2-pyridyldithio) propionate (SPDP). The four derivatives were covalently bound to tetanus toxoid (TT) by carbodiimide-mediated condensation or with SPDP to form conjugates. Immunization of BALB/c and general-purpose mice by a clinically acceptable route showed that DeA-LPS-TTADH, of the four conjugates, elicited the highest level of LPS antibodies. Possible reasons to explain this differential immunogenicity between the four conjugates are discussed.

Full Text

The Full Text of this article is available as a PDF (342.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson P. W., Pichichero M. E., Stein E. C., Porcelli S., Betts R. F., Connuck D. M., Korones D., Insel R. A., Zahradnik J. M., Eby R. Effect of oligosaccharide chain length, exposed terminal group, and hapten loading on the antibody response of human adults and infants to vaccines consisting of Haemophilus influenzae type b capsular antigen unterminally coupled to the diphtheria protein CRM197. J Immunol. 1989 Apr 1;142(7):2464–2468. [PubMed] [Google Scholar]
  2. Baumgartner J. D., Heumann D., Calandra T., Glauser M. P. Antibodies to lipopolysaccharides after immunization of humans with the rough mutant Escherichia coli J5. J Infect Dis. 1991 Apr;163(4):769–772. doi: 10.1093/infdis/163.4.769. [DOI] [PubMed] [Google Scholar]
  3. Bitzan M., Karch H., Maas M. G., Meyer T., Rüssmann H., Aleksić S., Bockemühl J. Clinical and genetic aspects of Shiga-like toxin production in traditional enteropathogenic Escherichia coli. Zentralbl Bakteriol. 1991 Jan;274(4):496–506. doi: 10.1016/s0934-8840(11)80087-3. [DOI] [PubMed] [Google Scholar]
  4. Campos L. C., Whittam T. S., Gomes T. A., Andrade J. R., Trabulsi L. R. Escherichia coli serogroup O111 includes several clones of diarrheagenic strains with different virulence properties. Infect Immun. 1994 Aug;62(8):3282–3288. doi: 10.1128/iai.62.8.3282-3288.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chu C. Y., Liu B. K., Watson D., Szu S. S., Bryla D., Shiloach J., Schneerson R., Robbins J. B. Preparation, characterization, and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type 1 (Shiga's bacillus) bound to tetanus toxoid. Infect Immun. 1991 Dec;59(12):4450–4458. doi: 10.1128/iai.59.12.4450-4458.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chu C., Schneerson R., Robbins J. B., Rastogi S. C. Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates. Infect Immun. 1983 Apr;40(1):245–256. doi: 10.1128/iai.40.1.245-256.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cryz S. J., Jr, Sadoff J. C., Fürer E. Immunization with a Pseudomonas aeruginosa immunotype 5 O polysaccharide-toxin A conjugate vaccine: effect of a booster dose on antibody levels in humans. Infect Immun. 1988 Jul;56(7):1829–1830. doi: 10.1128/iai.56.7.1829-1830.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. DeMaria A., Jr, Johns M. A., Berberich H., McCabe W. R. Immunization with rough mutants of Salmonella minnesota: initial studies in human subjects. J Infect Dis. 1988 Aug;158(2):301–311. doi: 10.1093/infdis/158.2.301. [DOI] [PubMed] [Google Scholar]
  9. Donnenberg M. S., Donohue-Rolfe A., Keusch G. T. Epithelial cell invasion: an overlooked property of enteropathogenic Escherichia coli (EPEC) associated with the EPEC adherence factor. J Infect Dis. 1989 Sep;160(3):452–459. doi: 10.1093/infdis/160.3.452. [DOI] [PubMed] [Google Scholar]
  10. Edstrom R. D., Heath E. C. Isolation of colitose-containing oligosaccharides from the cell wall lipopolysaccharide of Escherichia coli. Biochem Biophys Res Commun. 1965 Dec 21;21(6):638–643. doi: 10.1016/0006-291x(65)90534-6. [DOI] [PubMed] [Google Scholar]
  11. Fattom A., Shiloach J., Bryla D., Fitzgerald D., Pastan I., Karakawa W. W., Robbins J. B., Schneerson R. Comparative immunogenicity of conjugates composed of the Staphylococcus aureus type 8 capsular polysaccharide bound to carrier proteins by adipic acid dihydrazide or N-succinimidyl-3-(2-pyridyldithio)propionate. Infect Immun. 1992 Feb;60(2):584–589. doi: 10.1128/iai.60.2.584-589.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Fattom A., Vann W. F., Szu S. C., Sutton A., Li X., Bryla D., Schiffman G., Robbins J. B., Schneerson R. Synthesis and physicochemical and immunological characterization of pneumococcus type 12F polysaccharide-diphtheria toxoid conjugates. Infect Immun. 1988 Sep;56(9):2292–2298. doi: 10.1128/iai.56.9.2292-2298.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Goldman R. C., Joiner K., Leive L. Serum-resistant mutants of Escherichia coli O111 contain increased lipopolysaccharide, lack an O antigen-containing capsule, and cover more of their lipid A core with O antigen. J Bacteriol. 1984 Sep;159(3):877–882. doi: 10.1128/jb.159.3.877-882.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Goldman R. C., Leive L. Heterogeneity of antigenic-side-chain length in lipopolysaccharide from Escherichia coli 0111 and Salmonella typhimurium LT2. Eur J Biochem. 1980;107(1):145–153. doi: 10.1111/j.1432-1033.1980.tb04635.x. [DOI] [PubMed] [Google Scholar]
  15. Goldman R. C., White D., Orskov F., Orskov I., Rick P. D., Lewis M. S., Bhattacharjee A. K., Leive L. A surface polysaccharide of Escherichia coli O111 contains O-antigen and inhibits agglutination of cells by O-antiserum. J Bacteriol. 1982 Sep;151(3):1210–1221. doi: 10.1128/jb.151.3.1210-1221.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Gupta R. K., Szu S. C., Finkelstein R. A., Robbins J. B. Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin. Infect Immun. 1992 Aug;60(8):3201–3208. doi: 10.1128/iai.60.8.3201-3208.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Hoffman W. D., Pollack M., Banks S. M., Koev L. A., Solomon M. A., Danner R. L., Koles N., Guelde G., Yatsiv I., Mouginis T. Distinct functional activities in canine septic shock of monoclonal antibodies specific for the O polysaccharide and core regions of Escherichia coli lipopolysaccharide. J Infect Dis. 1994 Mar;169(3):553–561. doi: 10.1093/infdis/169.3.553. [DOI] [PubMed] [Google Scholar]
  18. Joiner K. A., Fries L. F., Schmetz M. A., Frank M. M. IgG bearing covalently bound C3b has enhanced bactericidal activity for Escherichia coli 0111. J Exp Med. 1985 Sep 1;162(3):877–889. doi: 10.1084/jem.162.3.877. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Joiner K. A., Schmetz M. A., Goldman R. C., Leive L., Frank M. M. Mechanism of bacterial resistance to complement-mediated killing: inserted C5b-9 correlates with killing for Escherichia coli O111B4 varying in O-antigen capsule and O-polysaccharide coverage of lipid A core oligosaccharide. Infect Immun. 1984 Jul;45(1):113–117. doi: 10.1128/iai.45.1.113-117.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. KAUFFMANN F., DUPONT A. Escherichia strains from infantile epidemic gastro enteritis. Acta Pathol Microbiol Scand. 1950;27(4):552–564. doi: 10.1111/j.1699-0463.1950.tb04927.x. [DOI] [PubMed] [Google Scholar]
  21. KESSNER D. M., SHAUGHNESSY H. J., GOOGINS J., RASMUSSEN C. M., ROSE N. J., MARSHALL A. L., Jr, ANDELMAN S. L., HALL J. B., ROSENBLOOM P. J. An extensive community outbreak of diarrhea due to enteropathogenic Escherichia coli 0111:B4. I. Epidemiologic studies. Am J Hyg. 1962 Jul;76:27–43. doi: 10.1093/oxfordjournals.aje.a120262. [DOI] [PubMed] [Google Scholar]
  22. Konadu E., Robbins J. B., Shiloach J., Bryla D. A., Szu S. C. Preparation, characterization, and immunological properties in mice of Escherichia coli O157 O-specific polysaccharide-protein conjugate vaccines. Infect Immun. 1994 Nov;62(11):5048–5054. doi: 10.1128/iai.62.11.5048-5054.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Levine M. M., Edelman R. Enteropathogenic Escherichia coli of classic serotypes associated with infant diarrhea: epidemiology and pathogenesis. Epidemiol Rev. 1984;6:31–51. doi: 10.1093/oxfordjournals.epirev.a036274. [DOI] [PubMed] [Google Scholar]
  24. Morrison D. C., Leive L. Fractions of lipopolysaccharide from Escherichia coli O111:B4 prepared by two extraction procedures. J Biol Chem. 1975 Apr 25;250(8):2911–2919. [PubMed] [Google Scholar]
  25. NETER E., KORNS R. F., TRUSSEL R. E. Association of Escherichia coli serogroup 0111 with two hospital outbreaks of epidemic diarrhea of the newborn infant in New York State during 1947. Pediatrics. 1953 Oct;12(4):377–383. [PubMed] [Google Scholar]
  26. OLARTE J., VARELA G. A complete somatic antigen common to Salmonella adelaide, Escherichia coli-gomez, and Escherichia coli 0111:B4. J Lab Clin Med. 1952 Aug;40(2):252–254. [PubMed] [Google Scholar]
  27. Oishi K., Koles N. L., Guelde G., Pollack M. Antibacterial and protective properties of monoclonal antibodies reactive with Escherichia coli O111:B4 lipopolysaccharide: relation to antibody isotype and complement-fixing activity. J Infect Dis. 1992 Jan;165(1):34–45. doi: 10.1093/infdis/165.1.34. [DOI] [PubMed] [Google Scholar]
  28. Orskov F., Orskov I. Escherichia coli serotyping and disease in man and animals. Can J Microbiol. 1992 Jul;38(7):699–704. [PubMed] [Google Scholar]
  29. Peeters C. C., Tenbergen-Meekes A. M., Evenberg D. E., Poolman J. T., Zegers B. J., Rijkers G. T. A comparative study of the immunogenicity of pneumococcal type 4 polysaccharide and oligosaccharide tetanus toxoid conjugates in adult mice. J Immunol. 1991 Jun 15;146(12):4308–4314. [PubMed] [Google Scholar]
  30. Pluschke G., Achtman M. Antibodies to O-antigen of lipopolysaccharide are protective against neonatal infection with Escherichia coli K1. Infect Immun. 1985 Aug;49(2):365–370. doi: 10.1128/iai.49.2.365-370.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Polotsky V. Y., Robbins J. B., Bryla D., Schneerson R. Comparison of conjugates composed of lipopolysaccharide from Shigella flexneri type 2a detoxified by two methods and bound to tetanus toxoid. Infect Immun. 1994 Jan;62(1):210–214. doi: 10.1128/iai.62.1.210-214.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Regua A. H., Bravo V. L., Leal M. C., Lobo Leite M. E. Epidemiological survey of the enteropathogenic Escherichia coli isolated from children with diarrhoea. J Trop Pediatr. 1990 Aug;36(4):176–179. doi: 10.1093/tropej/36.4.176. [DOI] [PubMed] [Google Scholar]
  33. Robbins J. B., Chu C., Schneerson R. Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides. Clin Infect Dis. 1992 Aug;15(2):346–361. doi: 10.1093/clinids/15.2.346. [DOI] [PubMed] [Google Scholar]
  34. Schwartzer T. A., Alcid D. V., Numsuwan V., Gocke D. J. Characterization of the human antibody response to an Escherichia coli O111:B4 (J5) vaccine. J Infect Dis. 1988 Nov;158(5):1135–1136. doi: 10.1093/infdis/158.5.1135. [DOI] [PubMed] [Google Scholar]
  35. Senerwa D., Olsvik O., Mutanda L. N., Lindqvist K. J., Gathuma J. M., Fossum K., Wachsmuth K. Enteropathogenic Escherichia coli serotype O111:HNT isolated from preterm neonates in Nairobi, Kenya. J Clin Microbiol. 1989 Jun;27(6):1307–1311. doi: 10.1128/jcm.27.6.1307-1311.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Szu S. C., Schneerson R., Robbins J. B. Rabbit antibodies to the cell wall polysaccharide of Streptococcus pneumoniae fail to protect mice from lethal challenge with encapsulated pneumococci. Infect Immun. 1986 Nov;54(2):448–455. doi: 10.1128/iai.54.2.448-455.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Szu S. C., Stone A. L., Robbins J. D., Schneerson R., Robbins J. B. Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals. J Exp Med. 1987 Nov 1;166(5):1510–1524. doi: 10.1084/jem.166.5.1510. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Taylor D. N., Trofa A. C., Sadoff J., Chu C., Bryla D., Shiloach J., Cohen D., Ashkenazi S., Lerman Y., Egan W. Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids. Infect Immun. 1993 Sep;61(9):3678–3687. doi: 10.1128/iai.61.9.3678-3687.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Tsai C. M. The analysis of lipopolysaccharide (endotoxin) in meningococcal polysaccharide vaccines by silver staining following SDS-polyacrylamide gel electrophoresis. J Biol Stand. 1986 Jan;14(1):25–33. doi: 10.1016/s0092-1157(86)80006-3. [DOI] [PubMed] [Google Scholar]
  40. Viljanen M. K., Peltola T., Junnila S. Y., Olkkonen L., Järvinen H., Kuistila M., Huovinen P. Outbreak of diarrhoea due to Escherichia coli O111:B4 in schoolchildren and adults: association of Vi antigen-like reactivity. Lancet. 1990 Oct 6;336(8719):831–834. doi: 10.1016/0140-6736(90)92337-h. [DOI] [PubMed] [Google Scholar]
  41. WARREN L. The thiobarbituric acid assay of sialic acids. J Biol Chem. 1959 Aug;234(8):1971–1975. [PubMed] [Google Scholar]
  42. Whittam T. S., Wolfe M. L., Wachsmuth I. K., Orskov F., Orskov I., Wilson R. A. Clonal relationships among Escherichia coli strains that cause hemorrhagic colitis and infantile diarrhea. Infect Immun. 1993 May;61(5):1619–1629. doi: 10.1128/iai.61.5.1619-1629.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES